NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at

Equities researchers at started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Rating) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NovaBay Pharmaceuticals stock opened at $2.08 on Monday. The company has a 50-day simple moving average of $0.23 and a 200-day simple moving average of $0.23. The firm has a market capitalization of $3.87 million, a P/E ratio of -0.37 and a beta of 2.83. NovaBay Pharmaceuticals has a one year low of $2.02 and a one year high of $20.65.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Further Reading

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.